The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Open accessAbstract
Purpose: Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options. Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of transcription pathway in the pathogenesis and clinical course of pancreatic cancer. Patients and Methods: In this double-blind, phase II study, patients with metastatic pancreatic cancer who had experienced treatment failure with gemcitabine were randomly assigned 1:1 to the JAK1/JAK2 inhibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m 2 twice daily) or placebo plus capecitabine. The primary end point was overall survival (OS); secondary end points included progression-free survival, clinical benefit response, objective response rate, and safety. Prespecified subgroup analyses evaluated treatment heterogeneity and efficacy in patients with evidence of inflammation. Results: In the intent-to-treat population (ruxolitinib, n = 64; placebo, n = 63), the hazard ratio was 0.79 (95% CI, 0.53 to 1.18; P = .25) for OS and was 0.75 (95% CI, 0.52 to 1.10; P = .14) for progression-free survival. In a prespecified subgroup analysis of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (ie, 13 mg/L), OS was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI, 0.26 to 0.85; P = .011). Prolonged survival in this subgroup was supported by post hoc analyses of OS that categorized patients by the modified Glasgow Prognostic Score, a systemic inflammation–based prognostic system. Grade 3 or greater adverse events were observed with similar frequency in the ruxolitinib (74.6%) and placebo (81.7%) groups. Grade 3 or greater anemia was more frequent with ruxolitinib (15.3%; placebo, 1.7%). Conclusion: Ruxolitinib plus capecitabine was generally well tolerated and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) or gemcitabine plus albumin-bound paclitaxel is the current standard of care in the first-line setting for patients with metastatic disease.(4-6) Essentially all patients will experience disease progression on or be intolerant of first-line therapy, an…”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“0 (37-84) Karnofsky performance status, % 100 7 (10.”
Cancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · cited 3×
“In these clinical studies, ruxolitinib treatment resulted in reduced levels of proinflammatory cytokines, improved myelofibrosis-related symptoms, weight gain, and improved overall survival (OS) relative to placebo or standard therapy.(54-56) Given the role of the JAK/STAT pathway in the pathogenesis and clinical cour…”
BackgroundSelf-citationInflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · cited 3×
“In these clinical studies, ruxolitinib treatment resulted in reduced levels of proinflammatory cytokines, improved myelofibrosis-related symptoms, weight gain, and improved overall survival (OS) relative to placebo or standard therapy.(54-56) Given the role of the JAK/STAT pathway in the pathogenesis and clinical cour…”
BackgroundSelf-citationMcMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Self-citationUnderstanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Fearon, K. C., Voss, A. C., & Hustead, D. S. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1345 · Cited by 779
Proctor, M. J., Morrison, D. S., Talwar, D., Balmer, S. M., Fletcher, C. D., O’Reilly, D. S. J., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.028 · Cited by 757
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 2×
“In preclinical models, including pancreatic cancer, the JAK/STAT and related inflammatory pathways drive cancer progression.(25,45-53) In particular, proinflammatory cytokines and STAT3 were important for disease initiation and progression in a preclinical pancreatic cancer model.”
BackgroundGreen, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Xu, Q., Briggs, J., Park, S., Niu, G., Kortylewski, M., Zhang, S., Gritsko, T., Turkson, J., Kay, H., Semenza, G. L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208719 · Cited by 576
Wei, D., Le, X., Zheng, L., Wang, L., Frey, J. A., Gao, A. C., Peng, Z., Huang, S., Xiong, H. Q., Abbruzzese, J. L., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206122 · Cited by 558
National Failure to Operate on Early Stage Pancreatic Cancer
Bilimoria, K. Y., Bentrem, D. J., Ko, C. Y., Stewart, A. K., Winchester, D. P., & Talamonti, M. S. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180691579 · Cited by 554
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
McMillan, D. C., Crozier, J. E. M., Canna, K., Angerson, W. J., & McArdle, C. S. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0259-6 · Cited by 533
Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
Fukuda, A., Wang, S. C., Morris, J. P., Folias, A. E., Liou, A., Kim, G. E., Akira, S., Boucher, K. M., Firpo, M. A., Mulvihill, S. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.002 · Cited by 521
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Sansone, P., & Bromberg, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8907 · Cited by 515
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis
Chang, Q., Bournazou, E., Sansone, P., Berishaj, M., Gao, S. P., Daly, L., Wels, J., Theilen, T., Granitto, S., Zhang, X., et al. (2013) · Neoplasia · doi:10.1593/neo.13706 · Cited by 494
McMillan, D. C. (2008) · Proceedings of the Nutrition Society · doi:10.1017/s0029665108007131 · Cited by 472
Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., Koniaris, L. G., & Zimmers, T. A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2012 · Cited by 463
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422
STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413 · cited 3×
“In preclinical models, including pancreatic cancer, the JAK/STAT and related inflammatory pathways drive cancer progression.(25,45-53) In particular, proinflammatory cytokines and STAT3 were important for disease initiation and progression in a preclinical pancreatic cancer model.”
BackgroundRole of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
Silva, C. M. (2004) · Oncogene · doi:10.1038/sj.onc.1208159 · Cited by 403
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Seufferlein, T., Bachet, J. B., Van Cutsem, E., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds224 · Cited by 389
Stat3 regulates genes common to both wound healing and cancer
Dauer, D. J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S., Jove, R., & Haura, E. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208469 · Cited by 380
Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 370
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
Nguyen, D. P., Li, J., & Tewari, A. K. (2014) · BJU International · doi:10.1111/bju.12452 · Cited by 359
Pancreatic cancer: diagnosis and management.
Freelove, R., & Walling, A. D. (2006) · PubMed · Cited by 309
Jenkins, B. J., Grail, D., Nheu, T., Najdovska, M., Wang, B., Waring, P., Inglese, M., McLoughlin, R. M., Jones, S. A., Topley, N., et al. (2005) · Nature Medicine · doi:10.1038/nm1282 · Cited by 308
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Quintás-Cardama, A., Kantarjian, H., Cortes, J., & Verstovsek, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3264 · Cited by 290
The regulation of inflammation by interferons and their STATs
Rauch, I., Müller, M., & Decker, T. (2013) · JAK-STAT · doi:10.4161/jkst.23820 · Cited by 281
Scholz, A., Heinze, S., Detjen, K. M., Peters, M., Welzel, M., Hauff, P., Schirner, M., Wiedenmann, B., & Rosewicz, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01064-3 · Cited by 256
McMillan, D. C., Elahi, M. M., Sattar, N., Angerson, W. J., Johnstone, J., & McArdle, C. S. (2001) · Nutrition and Cancer · doi:10.1080/01635581.2001.9680613 · Cited by 250
Alvarez, J. V., Greulich, H., Sellers, W. R., Meyerson, M., & Frank, D. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3757 · Cited by 240
The immune network in pancreatic cancer development and progression
Wörmann, S. M., Diakopoulos, K. N., Lesina, M., & Algül, H. (2014) · Oncogene · doi:10.1038/onc.2013.257 · Cited by 205
Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology
(2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0035 · Cited by 181
Walford, H. H., & Doherty, T. A. (2013) · JAK-STAT · doi:10.4161/jkst.25301 · Cited by 177
Pancreatic Cancer as a Model: Inflammatory Mediators, Acute‐phase Response, and Cancer Cachexia
Fearon, K. C. H., Barber, M. D., Falconer, J. S., McMillan, D. C., Ross, J. A., & Preston, T. (1999) · World Journal of Surgery · doi:10.1007/pl00012351 · Cited by 175
Kermorgant, S., & Parker, P. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806076 · Cited by 174
Lai, S. Y., Childs, E. E., Xi, S., Coppelli, F. M., Gooding, W. E., Wells, A., Ferris, R. L., & Grandis, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208635 · Cited by 167
Laird, B. J. A., McMillan, D. C., Fayers, P. M., Fearon, K., Kaasa, S., Fallon, M., & Klepstad, P. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0120 · Cited by 166
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., Wang, L., Gooding, W. E., Johnson, D. E., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0792 · Cited by 158
Rahma, O. E., Duffy, A. G., Liewehr, D. J., Steinberg, S. M., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt166 · Cited by 140
Zhao, S., Venkatasubbarao, K., Lazor, J. W., Sperry, J. C., Jin, C., Cao, L., & Freeman, J. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5123 · Cited by 120
Prognostic Role of C-Reactive Protein in Breast Cancer: A Systematic Review and Meta-Analysis
Han, Y., Mao, F., Wu, Y., Fu, X., Zhang, W., Zhu, X., Zhou, S., Zhang, W., Sun, Q., & Zhao, Y. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8872 · Cited by 116
Guthrie, G. J. K., Roxburgh, C. S. D., Horgan, P. G., & McMillan, D. C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.003 · Cited by 113
Nixon, A. B., Pang, H., Starr, M. D., Friedman, P. N., Bertagnolli, M. M., Kindler, H. L., Goldberg, R. M., Venook, A. P., & Hurwitz, H. I. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0926 · Cited by 104
Self-citationInduction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells
Qu, X., Zhuang, G., Yu, L., Meng, G., & Ferrara, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.326801 · Cited by 102
Phesse, T. J., Büchert, M., Stuart, E. C., Flanagan, D. J., Faux, M. C., Afshar‐Sterle, S., Walker, F., Zhang, H., Nowell, C. J., Jorissen, R. N., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005411 · Cited by 82
The Role of Inflammation in Inflammatory Breast Cancer
Fouad, T. M., Kogawa, T., Reuben, J. M., & Ueno, N. T. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_3 · Cited by 71
Li, H., Huang, C., Huang, K., Wu, W. D., Jiang, T., Cao, J., Feng, Z., & Qiu, Z. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025941 · Cited by 69
Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer
Nakachi, K., Furuse, J., Ishii, H., Suzuki, E., & Yoshino, M. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl144 · Cited by 56
Ridker, P. M., Kastelein, J. J. P., Genest, J. J., & Köenig, W. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht022 · Cited by 39
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., & Tuveson, D. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0710 · Cited by 1,360
Metadata
- Authors
- Hurwitz, H. I., Uppal, N., Wagner, S. A., Bendell, J. C., Beck, J. T., Wade, S. M., Nemunaitis, J. J., Stella, P. J., Pipas, J. M., Wainberg, Z. A., Manges, R., Garrett, W. M., Hunter, D. S., Clark, J., Leopold, L., Sandor, V., & Levy, R. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-12-01
- Volume
- 33
- Issue
- 34
- Pages
- 4039-4047
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146147581
- Cited by
- 292
- References
- 64
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.